Name: Peter Ludwig at NYBA 22nd Annual Meeting
Start: 2013-05-29T05:00

Why Fish

Diversity, Equity & Inclusion

Pro Bono & Social Responsibility

Legal Operations

Pricing

Legal Project Management

Knowledge Management

eDiscovery

Legal Technology Services

Trademark, Copyright & Media Litigation

Trade Secret Litigation

Appellate

ITC Litigation & Section 337

Standard Essential Patents

Chancery & Corporate Governance

Post-Grant

Inter Partes Review

Post-Grant Review

Ex Parte Reexamination

Supplemental Examination

Patent

Patent Prosecution

Strategic Patent Counseling & Opinions

Patent Portfolio Management

Unitary Patent & Unified Patent Court

IP Licensing, Transactions & Agreements

Trademark & Copyright Counseling & Prosecution

Strategic Counseling, Registration & Opinions

Advertising & Marketing

Domain Names & Internet

TTAB Oppositions & Cancellations

Digital Millennium Copyright Act

Transactions & Agreements

Regulatory & Government Affairs

Communications & Spectrum Regulation

Drug & Medical Device Regulation

mHealth & Telemedicine

Privacy & Data Security

Industries

Electrical & Computer Technology

Artificial Intelligence

Digital Health

Digital Media & E-Commerce

Financial, Business & FinTech Services

Biotech & Diagnostics

Medical Devices

Pharmaceuticals

Academic Research & Medical Centers

Transportation, Aerospace & Defense

Post-Grant Annual Reports

Hosts

Name

S. Peter Ludwig

Person title

Senior Principal

Fish’s Peter Ludwig presented at the 22nd annual meeting of the NY Biotechnology Association.

NYBA 22nd Annual Meeting

Hosts

PTAB Bar Association Young Lawyers and Agents Committee Lunch & Learn Series: “What Is the PTAB?”

PTAB Bar Association Annual Conference 2026

LSX World Congress Europe 2026

IAM Live: SEP Summit Asia 2026

European Patent Officeto Increase Fees on April 1, 2026

Playing the Piano Makes Me a Better Lawyer

Adding to the SEP Toolkit: AI and SEP Analysis

5 in ’25: Standard Essential Patents

5 in ’25: Artificial Intelligence

PTAB Reverses § 101 Rejection Under Desjardins Framework

USPTO Launches SEP Working Group

Lessons From Recent Pharma & Med Device Federal Circuit Decisions

USPTO Adds Desjardins to MPEP Subject Matter Eligibility Guidance

USPTO Urges Separate Filing of Subject Matter Eligibility Declarations